Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurogene (NGNE)
NASDAQ:NGNE
Holding NGNE?
Track your performance easily
NGNE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.49 - $74.49
Previous Close$23.51
Volume280.42K
Average Volume (3M)361.72K
Market Cap
$493.23M
Enterprise Value$367.36M
Total Cash (Recent Filing)$138.99M
Total Debt (Recent Filing)$13.12M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Nov 18, 2024EPS Estimate
-$1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.49
Shares Outstanding14,854,725
10 Day Avg. Volume344,201
30 Day Avg. Volume361,718
Standard Deviation0.27
R-Squared0.06
Alpha-0.00825
Financial Highlights & Ratios
Price to Book (P/B)2.54
Price to Sales (P/S)377.55
Price to Cash Flow (P/CF)-5.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue397.15
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.69
Forecast
1Y Price Target
$55.80Price Target Upside122.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Neurogene News
PremiumCompany Announcements
Neurogene Adjusts Clinical Trial After Setback
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentNeurogene's NGN-401 shows impressive and durable benefits at a low dose for treating Rett syndrome, with all patients showing improvement.
Financial PositionNeurogene's financial position is robust, bolstered by substantial private placement proceeds, significantly extending its cash runway for future developments.
Regulatory ProgressThe FDA allowed Neurogene to proceed with low-dose NGN-401, confirming a favorable safety profile with only mild adverse events observed.
Bears Say
Program TerminationNGNE terminated the CLN5 Batten disease program citing lack of RMAT designation.
Safety ConcernsA patient died after exhibiting systemic hyperinflammatory syndrome—a rare, life-threatening immune response associated with high doses of adeno-associated virus (AAV).
Stock PressureNeurogene shares have come under significant pressure following emergence of a serious adverse event in the high-dose cohort.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NGNE FAQ
What was Neurogene’s price range in the past 12 months?
Neurogene lowest stock price was $12.49 and its highest was $74.49 in the past 12 months.
What is Neurogene’s market cap?
Currently, no data Available
When is Neurogene’s upcoming earnings report date?
Neurogene’s upcoming earnings report date is Nov 18, 2024 which is 33 days ago.
How were Neurogene’s earnings last quarter?
Neurogene released its earnings results on Aug 09, 2024. The company reported -$1.09 earnings per share for the quarter, missing the consensus estimate of -$1.05 by -$0.04.
Is Neurogene overvalued?
According to Wall Street analysts Neurogene’s price is currently Undervalued.
Does Neurogene pay dividends?
Neurogene does not currently pay dividends.
What is Neurogene’s EPS estimate?
Neurogene’s EPS estimate is -$1.22.
How many shares outstanding does Neurogene have?
Neurogene has 20,979,721 shares outstanding.
What happened to Neurogene’s price movement after its last earnings report?
Neurogene reported an EPS of -$1.09 in its last earnings report, missing expectations of -$1.05. Following the earnings report the stock price went down -13.068%.
Which hedge fund is a major shareholder of Neurogene?
Among the largest hedge funds holding Neurogene’s share is Baker Bros Advisors LP. It holds Neurogene’s shares valued at 19M.
---
Neurogene Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.80 (122.05% Upside)
$55.80 (122.05% Upside)
Blogger Sentiment
Bullish
NGNE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 83.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 88.5%
Last 30 Days ▲ 88.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
75.97%
12-Months-Change
Fundamentals
Return on Equity
-66.90%
Trailing 12-Months
Asset Growth
83.20%
Trailing 12-Months
Company Description
Neurogene
Neoleukin Therapeutics, Inc. is a biopharmaceutical company, which engages in the design of de novo protein therapeutics to address significant unmet medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.
---
NGNE Stock 12 Month Forecast
Average Price Target
$55.80
▲(122.05% Upside)
Technical Analysis
Best Analysts Covering NGNE
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
+0.37%
reiterated a buy rating last month
Copying Paul Matteis's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +0.37% per trade.
---